| Characteristic . | SubT (n = 19) . | LE (n = 19) . | Primed Combination (n = 24) . | Unprimed Combination (n = 10) . |
|---|---|---|---|---|
| Median age, y (range) | 56.1 (28–65) | 55.9 (27–76) | 60 (19–72) | 42 (24–64) |
| Sex, n (%) | ||||
| Male | 13 (68.4) | 11 (57.9) | 12 (50.0) | 6 (60.0) |
| Female | 6 (31.6) | 8 (42.1) | 12 (50.0) | 4 (40.0) |
| Race, n (%) | ||||
| White | 18 (94.7) | 19 (100) | 24 (100) | 10 (100) |
| Asian | 1 (5.3) | 0 | 0 | 0 |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 1 (5.3) | 3 (15.8) | 4 (16.7) | 4 (40.0) |
| Non-Hispanic or Latino | 18 (94.7) | 16 (84.2) | 20 (83.3) | 6 (60.0) |
| KPS, n (%) | ||||
| 90–100 | 15 (78.9) | 11 (57.9) | 9 (37.5) | 4 (40) |
| 70–80 | 4 (21.1) | 7 (36.8) | 14 (58.3) | 3 (30) |
| ≤60 | 0 | 1 (5.3) | 1 (4.2) | 0 |
| Unknown | 3 (30) | |||
| Initial surgery, n (%) | ||||
| Biopsy only | 2 (10.5) | 3 (15.8) | 5 (20.8) | 0 |
| Partial resection | 10 (52.6) | 10 (52.6) | 8 (33.3) | 5(50.0) |
| Complete resection | 6 (31.6) | 6 (31.6) | 9 (37.5) | 1 (10.0) |
| Other/unknown | 1 (5.3) | 0 | 2 (8.3) | 4 (40.0) |
| Recurrence, n (%) | ||||
| First | 13 (68.4) | 14 (73.7) | 13 (54.2) | 3 (30) |
| Second | 3 (15.8) | 3 (15.8) | 10 (41.7) | 3 (30) |
| >Second | 3 (15.8) | 2 (10.5) | 1 (4.2) | 4(40) |
| No. of target lesions, n (%) | ||||
| 1 | 17 (89.5) | 15 (78.9) | 22 (91.7) | 4 (40%) |
| >1 | 2 (10.5) | 4 (21.1) | 2 (8.3) | 6 (60%) |
| Tumor area (mm2) mean, mediana | 794, 555 | 1107, 693 | 1388, 1064 | 3205, 3036 |
| No. of prior lines of therapy | ||||
| 1, n (%) | 13 (68.4) | 14 (73.7) | 16 (66.7) | 6 (60.0) |
| 2, n (%) | 3 (15.8) | 3 (15.8) | 8 (33.3) | 3 (30.0) |
| >2, n (%) | 3 (15.8) | 2 (10.5) | 0 | 1 (10.0) |
| MGMT methylation status, n (%) | ||||
| Methylated | 4 (21.1) | 4 (21.1) | 9 (37.5) | |
| Unmethylated | 5 (26.3) | 10 (52.6) | 5 (20.8) | |
| Unknown | 10 (52.6) | 5 (26.3) | 10 (41.7) | 10 (100) |
| Characteristic . | SubT (n = 19) . | LE (n = 19) . | Primed Combination (n = 24) . | Unprimed Combination (n = 10) . |
|---|---|---|---|---|
| Median age, y (range) | 56.1 (28–65) | 55.9 (27–76) | 60 (19–72) | 42 (24–64) |
| Sex, n (%) | ||||
| Male | 13 (68.4) | 11 (57.9) | 12 (50.0) | 6 (60.0) |
| Female | 6 (31.6) | 8 (42.1) | 12 (50.0) | 4 (40.0) |
| Race, n (%) | ||||
| White | 18 (94.7) | 19 (100) | 24 (100) | 10 (100) |
| Asian | 1 (5.3) | 0 | 0 | 0 |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 1 (5.3) | 3 (15.8) | 4 (16.7) | 4 (40.0) |
| Non-Hispanic or Latino | 18 (94.7) | 16 (84.2) | 20 (83.3) | 6 (60.0) |
| KPS, n (%) | ||||
| 90–100 | 15 (78.9) | 11 (57.9) | 9 (37.5) | 4 (40) |
| 70–80 | 4 (21.1) | 7 (36.8) | 14 (58.3) | 3 (30) |
| ≤60 | 0 | 1 (5.3) | 1 (4.2) | 0 |
| Unknown | 3 (30) | |||
| Initial surgery, n (%) | ||||
| Biopsy only | 2 (10.5) | 3 (15.8) | 5 (20.8) | 0 |
| Partial resection | 10 (52.6) | 10 (52.6) | 8 (33.3) | 5(50.0) |
| Complete resection | 6 (31.6) | 6 (31.6) | 9 (37.5) | 1 (10.0) |
| Other/unknown | 1 (5.3) | 0 | 2 (8.3) | 4 (40.0) |
| Recurrence, n (%) | ||||
| First | 13 (68.4) | 14 (73.7) | 13 (54.2) | 3 (30) |
| Second | 3 (15.8) | 3 (15.8) | 10 (41.7) | 3 (30) |
| >Second | 3 (15.8) | 2 (10.5) | 1 (4.2) | 4(40) |
| No. of target lesions, n (%) | ||||
| 1 | 17 (89.5) | 15 (78.9) | 22 (91.7) | 4 (40%) |
| >1 | 2 (10.5) | 4 (21.1) | 2 (8.3) | 6 (60%) |
| Tumor area (mm2) mean, mediana | 794, 555 | 1107, 693 | 1388, 1064 | 3205, 3036 |
| No. of prior lines of therapy | ||||
| 1, n (%) | 13 (68.4) | 14 (73.7) | 16 (66.7) | 6 (60.0) |
| 2, n (%) | 3 (15.8) | 3 (15.8) | 8 (33.3) | 3 (30.0) |
| >2, n (%) | 3 (15.8) | 2 (10.5) | 0 | 1 (10.0) |
| MGMT methylation status, n (%) | ||||
| Methylated | 4 (21.1) | 4 (21.1) | 9 (37.5) | |
| Unmethylated | 5 (26.3) | 10 (52.6) | 5 (20.8) | |
| Unknown | 10 (52.6) | 5 (26.3) | 10 (41.7) | 10 (100) |
a Sum of products of perpendicular diameters per central imaging assessment.
| Characteristic . | SubT (n = 19) . | LE (n = 19) . | Primed Combination (n = 24) . | Unprimed Combination (n = 10) . |
|---|---|---|---|---|
| Median age, y (range) | 56.1 (28–65) | 55.9 (27–76) | 60 (19–72) | 42 (24–64) |
| Sex, n (%) | ||||
| Male | 13 (68.4) | 11 (57.9) | 12 (50.0) | 6 (60.0) |
| Female | 6 (31.6) | 8 (42.1) | 12 (50.0) | 4 (40.0) |
| Race, n (%) | ||||
| White | 18 (94.7) | 19 (100) | 24 (100) | 10 (100) |
| Asian | 1 (5.3) | 0 | 0 | 0 |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 1 (5.3) | 3 (15.8) | 4 (16.7) | 4 (40.0) |
| Non-Hispanic or Latino | 18 (94.7) | 16 (84.2) | 20 (83.3) | 6 (60.0) |
| KPS, n (%) | ||||
| 90–100 | 15 (78.9) | 11 (57.9) | 9 (37.5) | 4 (40) |
| 70–80 | 4 (21.1) | 7 (36.8) | 14 (58.3) | 3 (30) |
| ≤60 | 0 | 1 (5.3) | 1 (4.2) | 0 |
| Unknown | 3 (30) | |||
| Initial surgery, n (%) | ||||
| Biopsy only | 2 (10.5) | 3 (15.8) | 5 (20.8) | 0 |
| Partial resection | 10 (52.6) | 10 (52.6) | 8 (33.3) | 5(50.0) |
| Complete resection | 6 (31.6) | 6 (31.6) | 9 (37.5) | 1 (10.0) |
| Other/unknown | 1 (5.3) | 0 | 2 (8.3) | 4 (40.0) |
| Recurrence, n (%) | ||||
| First | 13 (68.4) | 14 (73.7) | 13 (54.2) | 3 (30) |
| Second | 3 (15.8) | 3 (15.8) | 10 (41.7) | 3 (30) |
| >Second | 3 (15.8) | 2 (10.5) | 1 (4.2) | 4(40) |
| No. of target lesions, n (%) | ||||
| 1 | 17 (89.5) | 15 (78.9) | 22 (91.7) | 4 (40%) |
| >1 | 2 (10.5) | 4 (21.1) | 2 (8.3) | 6 (60%) |
| Tumor area (mm2) mean, mediana | 794, 555 | 1107, 693 | 1388, 1064 | 3205, 3036 |
| No. of prior lines of therapy | ||||
| 1, n (%) | 13 (68.4) | 14 (73.7) | 16 (66.7) | 6 (60.0) |
| 2, n (%) | 3 (15.8) | 3 (15.8) | 8 (33.3) | 3 (30.0) |
| >2, n (%) | 3 (15.8) | 2 (10.5) | 0 | 1 (10.0) |
| MGMT methylation status, n (%) | ||||
| Methylated | 4 (21.1) | 4 (21.1) | 9 (37.5) | |
| Unmethylated | 5 (26.3) | 10 (52.6) | 5 (20.8) | |
| Unknown | 10 (52.6) | 5 (26.3) | 10 (41.7) | 10 (100) |
| Characteristic . | SubT (n = 19) . | LE (n = 19) . | Primed Combination (n = 24) . | Unprimed Combination (n = 10) . |
|---|---|---|---|---|
| Median age, y (range) | 56.1 (28–65) | 55.9 (27–76) | 60 (19–72) | 42 (24–64) |
| Sex, n (%) | ||||
| Male | 13 (68.4) | 11 (57.9) | 12 (50.0) | 6 (60.0) |
| Female | 6 (31.6) | 8 (42.1) | 12 (50.0) | 4 (40.0) |
| Race, n (%) | ||||
| White | 18 (94.7) | 19 (100) | 24 (100) | 10 (100) |
| Asian | 1 (5.3) | 0 | 0 | 0 |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 1 (5.3) | 3 (15.8) | 4 (16.7) | 4 (40.0) |
| Non-Hispanic or Latino | 18 (94.7) | 16 (84.2) | 20 (83.3) | 6 (60.0) |
| KPS, n (%) | ||||
| 90–100 | 15 (78.9) | 11 (57.9) | 9 (37.5) | 4 (40) |
| 70–80 | 4 (21.1) | 7 (36.8) | 14 (58.3) | 3 (30) |
| ≤60 | 0 | 1 (5.3) | 1 (4.2) | 0 |
| Unknown | 3 (30) | |||
| Initial surgery, n (%) | ||||
| Biopsy only | 2 (10.5) | 3 (15.8) | 5 (20.8) | 0 |
| Partial resection | 10 (52.6) | 10 (52.6) | 8 (33.3) | 5(50.0) |
| Complete resection | 6 (31.6) | 6 (31.6) | 9 (37.5) | 1 (10.0) |
| Other/unknown | 1 (5.3) | 0 | 2 (8.3) | 4 (40.0) |
| Recurrence, n (%) | ||||
| First | 13 (68.4) | 14 (73.7) | 13 (54.2) | 3 (30) |
| Second | 3 (15.8) | 3 (15.8) | 10 (41.7) | 3 (30) |
| >Second | 3 (15.8) | 2 (10.5) | 1 (4.2) | 4(40) |
| No. of target lesions, n (%) | ||||
| 1 | 17 (89.5) | 15 (78.9) | 22 (91.7) | 4 (40%) |
| >1 | 2 (10.5) | 4 (21.1) | 2 (8.3) | 6 (60%) |
| Tumor area (mm2) mean, mediana | 794, 555 | 1107, 693 | 1388, 1064 | 3205, 3036 |
| No. of prior lines of therapy | ||||
| 1, n (%) | 13 (68.4) | 14 (73.7) | 16 (66.7) | 6 (60.0) |
| 2, n (%) | 3 (15.8) | 3 (15.8) | 8 (33.3) | 3 (30.0) |
| >2, n (%) | 3 (15.8) | 2 (10.5) | 0 | 1 (10.0) |
| MGMT methylation status, n (%) | ||||
| Methylated | 4 (21.1) | 4 (21.1) | 9 (37.5) | |
| Unmethylated | 5 (26.3) | 10 (52.6) | 5 (20.8) | |
| Unknown | 10 (52.6) | 5 (26.3) | 10 (41.7) | 10 (100) |
a Sum of products of perpendicular diameters per central imaging assessment.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
